Literature DB >> 6808692

Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state.

R Dal Bo Zanon, L Fornasiero, M Boscaro, G Cappellato, F Fabris, A Girolami.   

Abstract

Thirteen women and 2 men affected by Cushing's syndrome were investigated. The following parameters were used: plasma and urinary cortisol levels, factor VIII assay (antigen, activity and von Willebrand factor) together with other coagulative assays. Samples were taken before surgery or before medical and/or radiation therapy and every 30-50 days after treatment and continued for 11 months. Cortisol and factor VIII were increased before treatment and decreased slowly after treatment to become normal in 3-4 months. Other clotting tests did not show significant changes. It seems that high plasma cortisol levels may stimulate the production of factor VIII. Patients with Cushing's syndrome often exhibit thromboembolic complications after surgery. It is likely that the clotting abnormalities responsible for such complications is the increased factor VIII activities level.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6808692

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

1.  Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease.

Authors:  K Obuobie; J S Davies; A Ogunko; M F Scanlon
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

2.  Complications following adrenal surgery.

Authors:  M K McLeod
Journal:  J Natl Med Assoc       Date:  1991-02       Impact factor: 1.798

3.  Increased factor VIII/vWf levels in patients with reduced platelet number.

Authors:  A Casonato; F Fabris; M Boscaro; A Girolami
Journal:  Blut       Date:  1987-05

4.  Recurrent thromboembolism as a hallmark of Cushing's syndrome.

Authors:  A La Brocca; M Terzolo; A Pia; P Paccotti; P De Giuli; A Angeli
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

5.  Bilateral adrenalectomy for Cushing's syndrome: a comparison between laparoscopy and open surgery.

Authors:  F Porpiglia; C Fiori; S Bovio; P Destefanis; A Alì; C Terrone; D Fontana; R M Scarpa; A Tempia; M Terzolo
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

6.  A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Authors:  Marialuisa Zilio; Linda Mazzai; Maria Teresa Sartori; Mattia Barbot; Filippo Ceccato; Viviana Daidone; Alessandra Casonato; Graziella Saggiorato; Franco Noventa; Laura Trementino; Paolo Prandoni; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Endocrine       Date:  2015-06-26       Impact factor: 3.633

7.  Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.

Authors:  Amit Tirosh; Maya Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2017-02-22       Impact factor: 2.936

Review 8.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.

Authors:  S Koutroumpi; V Daidone; M T Sartori; M G Cattini; N M Albiger; G Occhi; S Ferasin; A Frigo; F Mantero; A Casonato; C Scaroni
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

10.  Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

Authors:  C Erem; I Nuhoglu; M Yilmaz; M Kocak; A Demirel; O Ucuncu; H Onder Ersoz
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.